Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system.

Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide (Lumixyl™) was previously shown to competitively inhibit mushroom and human tyrosinase in vitro without the associated cytotoxicity of hydroquinone and to diminish the appearance of facial melasma.The aim of this case study was to determine if the Lumixyl Topical Brightening System (0.01% oligopeptide cream, an antioxidant cleanser, 20% glycolic acid lotion and physical sunscreen) accelerates clearance of mild-to-moderate melasma.All patients showed improvement in their facial melasma with 1 of 4 patients showing complete clearance after just 6 weeks.Results suggest that this regimen may be a useful new tool to treat mild to moderate melasma.